
S8 Ep4: Beyond the Biologic Boom with Dr. Perry Grewal
Seven years after his first appearance on Dermalogues, Dr. Perry Grewal returns to talk with host Dr. Kerri Purdy about what’s changed in the treatment of psoriasis and atopic dermatitis. With more biologics available, how do you choose the right one for the patient in front of you?
They start with psoriasis and discuss how joint symptoms, other health conditions and injection schedules shape treatment choice. They share how they explain a switch to a biosimilar and how they approach decisions about continuing a biologic after a new cancer diagnosis.
The conversation then turns to atopic dermatitis, where they discuss counselling patients about side effects, recognizing paradoxical reactions and deciding when to give a treatment more time. To close, Dr. Grewal looks ahead at the Canadian treatment pipeline, from oral IL-23 peptides and new TYK2 inhibitors to longer-acting biologics that could mean fewer injections.
Special thanks to Dr. Fiona Landells, a dermatology resident at the University of Calgary, for asking what’s next in the Canadian pipeline and how those treatments might change conversations with patients.
Related listening
Revisit Dr. Grewal’s first Dermalogues appearance in Season 1, Episode 3 to hear how the conversation about psoriasis biologics has changed since 2019.
For more great CDA podcasts, check out JCMS Author Interviews with Dr Kirk Barber
To learn more about the work of the CDA, please visit dermatology.ca
Dermalogues is produced by David McGuffin and Graham McGuffin of ExploreProductions.ca
More episodes from "Dermalogues: The Dermatology Residents Podcast with Dr. Kerri Purdy"



Don't miss an episode of “Dermalogues: The Dermatology Residents Podcast with Dr. Kerri Purdy” and subscribe to it in the GetPodcast app.








